Article
Toxicity and Efficacy of a Novel GADD34-expressing Oncolytic HSV-1 for the Treatment of Experimental Glioblastoma.
Clinical cancer research : an official journal of the American Association for Cancer Research - 1 Jun 2018
Nakashima Hiroshi, Nguyen Tran, Kasai Kazue, Passaro Carmela, Ito Hirotaka, Goins William F, Shaikh Imran, Erdelyi Ronald, Nishihara Reiko, Nakano Ichiro, Reardon David A, Anderson Ana C, Kuchroo Vijay, Chiocca E Antonio
Abstract excerpt
Purpose: Glioblastoma (GBM) is the most common primary central nervous system cancer in adults. Oncolytic HSV-1 (oHSV) is the first FDA-approved gene therapy approach for the treatment of malignant melanoma. For GBM, oHSVs need to be engineered to replicate within and be toxic to the glial tumor but not to normal brain parenchymal cells. We have thus engineered a novel oHSV to achieve these...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.